Victoria Del Gaizo Moore, PhD
Assistant Professor of Chemistry
Ph.D., Molecular Medicine, 1999 - 2004
Wake Forest School of Medicine, Winston-Salem, NC
B.S., James Madison University, 1995 - 1999
Del Gaizo Moore V, Letai A. Rational design of therapeutics targeting the BCL-2 family: are some cancer cells primed for death but waiting for a final push? Adv Exp Med Biol. 2008;615:159-75. Review.
Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood. 2008 Feb 15;111(4):2300-9.
Del Gaizo Moore, V., Brown, J.R., Certo, M., Love, T.M., Novina, C.D., and A. Letai. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. JCI, January 2007, 117(1): 112-121.
Certo M., Del Gaizo Moore V., Nishino, M., Wei G., Korsmeyer, S., Armstrong, S.A., and A. Letai. Cellular Addiction to Antiapoptotic BCL-Family Proteins Revealed by Mitochondrial Sensitivity to Sensitizer BH3 Peptides and ABT-737. Cancer Cell, May 2006, 9: 351-365.
Angdison J., Del Gaizo Moore V., Cline J.M. Payne, R.M., and J.A. Ibdah. Mitochondrial Trifunctional Protein Defects: Molecular Basis and Novel Therapeutic Approaches. CTD-IEMD, March 2005: 5(1): 27-40
Del Gaizo Moore, V. and Letai, A. 2006. In press. "Rational Design of Therapeutics Targeting the Bcl-2 family" in Programmed Cell Death in Cancer Progression and Therapy. Springer Publishing.
For a listing of additional publications, refer to PubMed, a service provided by the National Library of Medicine.
American Cancer Society Post-doctoral Fellowship
“Targeting BCL-2 Addiction in Leukemia”